Background Lupus nephritis can affect up to 70% of the SLE population elevated serum IL-10 levels were observed in SLE patients and have been shown to be associated with disease activity. It enhances B-cell surivival, proliferation, differentiation, Genotypic variations in the human IL-10 promoter may account for individual variation in IL-10 production and in turn, susceptibility to a particular disease. Objectives to investigate the -592 A/C polymorphism in patients with lupus nephritis with different pathological classes and to assess its influence on IL-10 secretion in vivo. Methods Patients were divided into: – Group I: lupus nephritis group (40 patients). – Group 2: SLE non nephritis group (20 patients). All patients in this study were subjected to the following: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Immunological profiles: ANA (Antinuclear Antibody) Anti double stranded DNA titer (Anti-ds DNA) Determination of –592 A/C polymorphisms in the IL-10 gene promoter Detection of serum of IL-10 level. All SLE patients with clinical and laboratory evidence of renal involvement will be subjected to renal core biopsy. Results There is no statistically significant differences in the distribution of the 592 genotypes, or the alleles frequencies between (group 1) and (group 2). There is no statistically significant difference between AC/CC and AA genotypes with different clinical and laboratory parameters in (group 1).Renal biopsy is done for all 40 patients of (group 1). According to the ISN/RPS 2003 classification (96), 12 patients (30%) are classified as class III LN, 16 patients (40%) are classified as class IV LN, 7 patients (17.50) are classified as class V, 4 patients (10%) are classified as class IV+V and 1 patient (2.50%) is classified as class VI. Class I and class II are not detected in the study.According to activity and chronicity indices,(96) class IIIa, IVa and IVa+V are classified as active classes while class IIIc and IVc are classified as chronic classes. There was no statistical significant difference in the distribution of AC and CC genotypes among different LN classes. Decrease in serum level of serum IL-10 in both active and chronic classes of LN does not reach the statistical significance. Conclusions IL-10 gene –592 A/C polymorphism, was not associated with susceptibility to LN or the difference of the patients' serum IL-10 levels, References Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34-8. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34-8. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3084
Background SLE is characterized by the production of a wide range of autoantibodies and immune complexes that may lead to tissue injury. Among patients with Lupus Nephritis; those with proliferative lesions (class III and IV) had higher serum NO levels, and higher NO levels were associated with accumulation of renal damage Objectives Assess the level of serum Nitric oxide (NO) inLN patients and its relation to disease activity. Methods The study was conducted on: – Group I (A): 20 SLE patients without clinically apparent renal disease. – Group I (B): 20 SLE patients with lupus nephritis. Besides: 10 of age and sex matched healthy subjects were taken as control group. All patients were subjected to: detailed history taking and complete physical SLE Disease Activity Index (SLEDAI), and SLE disease damage index (SLEDDI) were applied for every lupus patient of the studied groups Laboratory investigations done for the studied group of patients included: – C3, C4, antinuclear antibodies (ANA) titre, antidouble stranded DNA antibodies (anti-ds DNA) titre, and serum Nitric Oxide. Renal biopsy in all the 20 cases with renal involvement were obtained – after an informed consent, and classified according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003, and was correlated with the serum level of NO. Results The mean serum Nitric oxide level was significantly higher in patients with renal involvement compared to those without renal involvement. It is also significantly higher in SLE patients than controls. The serum Nitric oxide level was correlated positively with ESR, anti ds-DNA antibodies level, 24 hr. urinary proteins, SLEDAI and pathological activity score in LN group, and showed negative correlation with creatinine clearance and serum level of C3 and C4. There was no significant correlation between serum NO and pathological chronicity score in LN group. There was no significant statistical difference between classes of Lupus nephritis as regards the mean value of serum Nitric oxide, although it was found to be higher in proliferative classes of Lupus nephritis (class IV and combined class IV and V) than non-proliferative Conclusions serum Nitric oxide can be used as an indicator for renal disease activity in SLE patients, and that it can be used in association with renal biopsy for estimating the class of renal involvement, correlation with renal disease activity References Jim C. Oates, Stephanie R. Shaftman, Sally E. Self and Gary S.Gilkeson. Association of serum Nitrate and Nitrite levels with longitudinal assessments of disease activity and damage in Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Rheum. 2008 January; 58(1): 263–272. Seok and Yun A. Kim. Correlation of serum Nitric oxide levels and disease activity of Systemic Lupus Erythematosus. Chonnam Medical Journal, Vol. 37, No. 2, pp. 119-123. Acknowledgements staff members and colleagues in Rheumatology Department,Alexandria Faculty of Medicine, Disclosure of Interest None declared DOI ...
Background Behçet’s disease gives a challenge to be diagnosed and followed up due to lack of specific biomarkers. MicroRNAs showed relations to different disease states including immunological and inflammatory illnesses. In this study, we are estimating microRNA548ac levels for the first time to be tested in the disease to see if there is a link to disease activity and if microRNA548ac can be used as a biomarker for activity or remission and prognosis of Behçet’s disease. MicroRNA548ac has been shown to have a role in autoimmunity and some inflammatory conditions. Blood samples were taken from patients to measure white blood cells expression of microRNA548ac, and compared to its expression in healthy subjects, disease activity was assessed by usage of Behçet’s Disease Current Activity Form (BDCAF). Results MicroRNA548ac expression decreased but not significantly with increased Behçet’s disease activity, and expression was having a significant positive correlation with increased treatment response history. Conclusions MicroRNA548ac appeared not to be related to disease activity which needs confirmation in further studies, but it may predict response to treatment so that patients having higher expression of microRNA548ac may have a better response to treatment. Here, microRNA548ac could be used as a disease biomarker for disease prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.